Michael Triplett, PhD
Michael Triplett, PhD
President, Carmen Partners, LLC
Carmen Partners
Dr. Triplett is president of Carmen Partners LLC. He was previously co-founder, president and CEO of Myonexus Therapeutics, a gene therapy research company focused on development of five pre-clinical and clinical stage candidates for Limb-girdle Muscular Dystrophy. Myonexus was sold to Sarepta Therapeutics in April 2019 for $165 million.